In a new study, researchers from research institutions such as the University of California, Los Angeles, discovered that advanced genome editing technology may be able to be used for a rare and fatal genetic disease, D3 delta severe combined immunodeficiency, CD3δ SCID, for a one-time treatment. The relevant research results were published online in Cell, with the title “Human T cell generation is restored in CD3δ severe combined immunodeficiency through…